UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

European respiratory review, 2016-12, Vol.25 (142), p.472-486

2016

Volltextzugriff (PDF)

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3337-3344

2012

Volltextzugriff (PDF)

Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015

British journal of cancer, 2019-11, Vol.121 (11), p.966-972

2019

Volltextzugriff (PDF)

What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial Discussions

Journal of clinical oncology, 2011-01, Vol.29 (1), p.61-68

2011

Volltextzugriff (PDF)

Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis

PloS one, 2016-09, Vol.11 (9), p.e0162809-e0162809

2016

Volltextzugriff (PDF)

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Clinical cancer research, 2010-12, Vol.16 (24), p.6150-6158

2010

Volltextzugriff (PDF)

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

European journal of cancer (1990), 2013-09, Vol.49 (13), p.2815-2822

2013

Volltextzugriff (PDF)

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

Clinical cancer research, 2004-10, Vol.10 (19), p.6528-6534

2004

Volltextzugriff (PDF)

Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1336-1343

2001

Volltextzugriff (PDF)

Association of Long-term Administration of the Survivin mRNA-Targeted Antisense Oligonucleotide LY2181308 With Reversible Kidney Injury in a Patient With Metastatic Melanoma

American journal of kidney diseases, 2011-02, Vol.57 (2), p.300-303

2011

Volltextzugriff (PDF)

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Clinical cancer research, 2007-03, Vol.13 (6), p.1816-1822

2007

Volltextzugriff (PDF)

Phase II Study of Vinflunine in Malignant Pleural Mesothelioma

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4751-4756

2007

Volltextzugriff (PDF)

Survivin in Solid Tumors: Rationale for Development of Inhibitors

Current oncology reports, 2012-04, Vol.14 (2), p.120-128

2012

Volltextzugriff (PDF)

Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma

Clinical cancer research, 2005-02, Vol.11 (4), p.1512-1520

2005

Volltextzugriff (PDF)

Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer

Clinical cancer research, 2001-07, Vol.7 (7), p.1912-1922

2001

Volltextzugriff (PDF)

Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma

Clinical cancer research, 2003-01, Vol.9 (1), p.84-92

2003

Volltextzugriff (PDF)

Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours

European journal of cancer (1990), 2014-03, Vol.50 (5), p.902-911

2014

Volltextzugriff (PDF)

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

Theranostics, 2011-01, Vol.1 (1), p.290-301

2011

Volltextzugriff (PDF)

Quantitative Analysis of Survivin Protein Expression and Its Therapeutic Depletion by an Antisense Oligonucleotide in Human Lung Tumors

Molecular therapy. Nucleic acids, 2012-06, Vol.1 (6), p.e30-e30, Article e30

2012

Volltextzugriff (PDF)

Isolation of a small molecule inhibitor of DNA base excision repair

Nucleic acids research, 2005-01, Vol.33 (15), p.4711-4724

2005

Volltextzugriff (PDF)

A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis

Clinical cancer research, 2000-12, Vol.6 (12), p.4697-4704

2000

Volltextzugriff (PDF)

Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase IIα Expression

Clinical cancer research, 2003-10, Vol.9 (13), p.4682-4688

2003

Volltextzugriff (PDF)

Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors

JAMA oncology, 2017-02, Vol.3 (2), p.275

2017

Volltextzugriff (PDF)

In Reply: Response to Marioni

Current oncology reports, 2013-02, Vol.15 (1), p.3-3

2013

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(68)

Sprache

Englisch
(61)
Französisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(42)
Humans
(38)
Oncology
(32)
Biological And Medical Sciences
(29)
Female
(29)
Medical Sciences
(28)
Middle Aged
(28)
Male
(26)
Aged
(25)
Adult
(24)
Pharmacology. Drug Treatments
(21)
Antineoplastic Agents
(19)
Chemotherapy
(16)
Treatment Outcome
(11)
Tumors
(9)
Dose-Response Relationship, Drug
(8)
Aged, 80 And Over
(7)
Antineoplastic Agents - Therapeutic Use
(7)
Lung Neoplasms - Pathology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015

What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial Discussions

Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin

Association of Long-term Administration of the Survivin mRNA-Targeted Antisense Oligonucleotide LY2181308 With Reversible Kidney Injury in a Patient With Metastatic Melanoma

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Phase II Study of Vinflunine in Malignant Pleural Mesothelioma

Survivin in Solid Tumors: Rationale for Development of Inhibitors

Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma

Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer

Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma

Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

Quantitative Analysis of Survivin Protein Expression and Its Therapeutic Depletion by an Antisense Oligonucleotide in Human Lung Tumors

Isolation of a small molecule inhibitor of DNA base excision repair

A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis

Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase IIα Expression

Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors

In Reply: Response to Marioni

Suchergebnisse filtern